Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SCYX 
Scynexis Inc (SCYX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: SCYX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.67
1 Year Target Price $3.67
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -74.32% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 28.96M USD | Price to earnings Ratio - | 1Y Target Price 3.67 |
Price to earnings Ratio - | 1Y Target Price 3.67 | ||
Volume (30-day avg) 3 | Beta 1.37 | 52 Weeks Range 0.56 - 1.49 | Updated Date 12/1/2025 |
52 Weeks Range 0.56 - 1.49 | Updated Date 12/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.51 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.2 | Actual -0.17 |
Profitability
Profit Margin - | Operating Margin (TTM) -2516.47% |
Management Effectiveness
Return on Assets (TTM) -28.85% | Return on Equity (TTM) -53.29% |
Valuation
Trailing PE - | Forward PE 3.21 | Enterprise Value -6683914 | Price to Sales(TTM) 9.88 |
Enterprise Value -6683914 | Price to Sales(TTM) 9.88 | ||
Enterprise Value to Revenue 0.44 | Enterprise Value to EBITDA 0.05 | Shares Outstanding 41965058 | Shares Floating 33056296 |
Shares Outstanding 41965058 | Shares Floating 33056296 | ||
Percent Insiders 2.16 | Percent Institutions 28.09 |
Upturn AI SWOT
Scynexis Inc
Company Overview
History and Background
Scynexis, Inc. is a biotechnology company focused on developing and commercializing novel anti-infectives to address significant unmet needs in the treatment of life-threatening fungal infections. Founded in 1999, they have focused on developing their lead product, Brexafemme (ibrexafungerp).
Core Business Areas
- Pharmaceutical Development and Commercialization: Focuses on the research, development, and commercialization of anti-infective drugs, particularly in the area of fungal infections.
Leadership and Structure
The leadership team includes executives specializing in drug development, finance, and commercialization. The organizational structure is typical of a publicly traded biotechnology company.
Top Products and Market Share
Key Offerings
- Brexafemme (ibrexafungerp): An oral antifungal indicated for the treatment of vulvovaginal candidiasis (VVC). Limited market share currently. Competitors include generic and branded azoles (fluconazole, etc.). Revenue is growing. Competitors include Pfizer (DIFLUCAN)
Market Dynamics
Industry Overview
The anti-infectives market is characterized by a growing need for novel therapies to combat drug-resistant infections. The market is driven by increasing incidence of fungal infections, particularly in immunocompromised patients.
Positioning
Scynexis is positioned as a company providing a novel oral antifungal, ibrexafungerp, targeting VVC and exploring other indications. Their competitive advantage lies in the novel mechanism of action of their drug.
Total Addressable Market (TAM)
The TAM for anti-fungal therapies is significant, estimated in the billions of dollars globally. Scynexis is positioned to capture a portion of this TAM through Brexafemme and future developments.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action (fungal cell wall)
- Oral formulation
- Potential for broad-spectrum activity
Weaknesses
- Limited commercial infrastructure
- Reliance on single product (Brexafemme)
- Financial resources
- Market adoption challenges of new drug class
Opportunities
- Expansion into new indications (e.g., invasive fungal infections)
- Partnerships with larger pharmaceutical companies
- Geographic expansion
- Further clinical data supporting efficacy and safety
Threats
- Competition from established antifungals
- Generic erosion
- Regulatory hurdles
- Failure in clinical trials
Competitors and Market Share
Key Competitors
- PFE
- GILD
- MRK
Competitive Landscape
Scynexis faces competition from larger pharmaceutical companies with established anti-infective portfolios. Its advantage lies in the novelty of its drug and potential for niche markets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by progress in clinical development and regulatory approvals. Actual Historical Growth: Revenue data: [10000000, 25000000, 30000000]
Future Projections: Future growth is dependent on the successful commercialization of Brexafemme and expansion into new indications. Dummy Future Projections: Revenue data: [40000000, 60000000, 80000000]
Recent Initiatives: Recent initiatives include commercial launch activities for Brexafemme and ongoing clinical trials.
Summary
Scynexis is a biotechnology company with a novel antifungal, Brexafemme, targeting VVC and other indications. Its strength lies in the novel mechanism, but it faces commercialization challenges and competition from larger companies. Future growth depends on successful commercialization and expansion into new markets. Monitoring cash burn rate and securing partnerships are crucial for long-term success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC filings
- Company website
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scynexis Inc
Exchange NASDAQ | Headquaters Jersey City, NJ, United States | ||
IPO Launch date 2014-05-02 | CEO, President & Director Dr. David Gonzalez Angulo M.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 28 | Website https://www.scynexis.com |
Full time employees 28 | Website https://www.scynexis.com | ||
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.